DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,993 filers reported holding DANAHER CORPORATION in Q3 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $162,257 | -9.7% | 654 | -12.7% | 0.02% | -19.2% |
Q2 2023 | $179,760 | +14.1% | 749 | +19.8% | 0.03% | +30.0% |
Q1 2023 | $157,525 | +45.1% | 625 | +52.8% | 0.02% | +53.8% |
Q4 2022 | $108,557 | +16.7% | 409 | +13.3% | 0.01% | +8.3% |
Q3 2022 | $93,000 | -9.7% | 361 | -10.9% | 0.01% | 0.0% |
Q2 2022 | $103,000 | -52.5% | 405 | -45.2% | 0.01% | -60.0% |
Q1 2022 | $217,000 | -21.1% | 739 | -11.6% | 0.03% | -26.8% |
Q4 2021 | $275,000 | -1.4% | 836 | -8.8% | 0.04% | -12.8% |
Q3 2021 | $279,000 | -29.4% | 917 | -37.7% | 0.05% | -19.0% |
Q2 2021 | $395,000 | +36.7% | 1,472 | +14.6% | 0.06% | +18.4% |
Q1 2021 | $289,000 | -59.7% | 1,284 | -60.3% | 0.05% | -83.3% |
Q4 2020 | $718,000 | +27.5% | 3,233 | +23.6% | 0.29% | +1.7% |
Q3 2020 | $563,000 | +0.4% | 2,615 | -17.5% | 0.29% | -3.3% |
Q2 2020 | $561,000 | -39.4% | 3,171 | -82.6% | 0.30% | -41.5% |
Q1 2020 | $926,000 | – | 18,177 | – | 0.51% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |